



10th Annual

Microbiome EUROPE Movement Summit

The Home of Accelerating Microbiome R&D

Translate the Latest Microbiome Science into Validated Clinical Impact to Strengthen Investor Confidence & Deliver Safe, Effective Microbiome Therapies & Products to Patients in Need

Your Expert Speaker Faculty Includes:



Claudio Hidalgo
Chief Executive Officer
Microviable Therapeutics



Rikke Nielsen
Founder & Chief Executive Officer
BEO Therapeutics



Jason Goldsmith
Senior Director, Medical, Translational
& Data Sciences
Nestlé Health Science



Jelena Cvejic
Visiting Professor
KU Leuven



Tomas de Wouters
Chief Executive Officer
PharmaBiome



Denise Kelly
Investment Advisor,
Health For Life
Seventure Partners

Lead Partner:



What Your Community Have to Say:

■ ■ This forum is the best way to collect the latest insights and news from the microbiome field ■ ■

Benjamin Hadida,
Chief Executive Officer
& Co-Founder, **Exelium Biosciences**, Past Attendee

■ ■ It feels as though the microbiome industry is starting to gain some more meat on its bones, with more late-stage clinical data emerging in new areas outside of infectious disease. This event hit the right balance between quality and quantity of attendees ■ ■

Nigel Titford, Head,
Business Development,
BioGaia, Past Attendee

■ ■ This meeting attracted a strong presence of CDMOs, VCs and microbiome-based drug developers ■ ■

Alberto Barros, CINO,
Bac3Gel, Past Partner

Celebrate 10 Years of the Microbiome Movement Europe

With the field expanding beyond gastrointestinal indications into oncology, dermatology, CNS, and women's health, and following **MaaT Pharma's** milestone EMA submission, the industry sits poised for significant breakthroughs. Yet, challenges persist. Clinical translation remains difficult, regulatory clarity is still evolving, and funding is increasingly competitive.

It is at this pivotal stage in microbiome drug development that the **10th Microbiome Movement Summit Europe** returns to drive the conversation forward.

Sessions on trial design and patient stratification will equip you to generate robust clinical data that convinces regulators and accelerates approvals. Manufacturing and regulator-focused content will help you reduce cost-of-goods and improve scalability enabling commercial preparedness.

With a modality agnostic approach covering live biotherapeutic products, faecal microbiota transplants, and consumer-facing products, this year's program reflects the full spectrum of microbiome innovation.

Whether you're advancing a drug candidate or leveraging consumer strategies to fund R&D, this meeting offers the knowledge, connections, and momentum to move your pipeline forward.

Join the European microbiome community in tackling shared obstacles, celebrating progress, and shaping the future of microbiome therapeutics - alongside leading voices from biotech, consumer health, solution providers, investment and academia.

What's New For 2026?



Harness Artificial Intelligence & Data Science for Microbiome Drug Discovery: Explore how **Amsterdam University Medical Centre** are using cutting-edge tools like metagenomics, and predictive modelling are being used to optimise patient selection, refine therapeutic targets, and accelerate discovery.



The Rise of Consumer Microbiome Products & Alternative Partnership Models: Learn how companies are using direct-to-consumer strategies to generate revenue and support costly R&D, with case studies from **Nestlé Health Science** and **Procter & Gamble** showcasing how this approach complements clinical development.



Hear Investor Perspectives & Pitching Sessions: Hear directly from investors like **Seventure Partners**, **CSB** and **ZCube** on what they are looking for in microbiome ventures and take part in dedicated sessions designed to help companies and attract funding.



Expanding to Non-Gastrointestinal Indications: Gain insights into how the microbiome is being applied in areas such as women's health, the gut-brain axis, dermatology, and immuno-oncology, with real-world examples from **Microviable Therapeutics** and **Ancilia Biosciences**.



Mechanistic Understanding to Support Clinical Translation: Dive deeper into how **AOBiome Therapeutics** and **PharmaBiome** are linking mechanism of action to clinical relevance, with sessions focused on improving trial design, regulatory engagement, and therapeutic validation.

Your Expert Speakers



Wouter De Jonge
Professor, Experimental
Gastroenterology
**Amsterdam University
Medical Center**



**Konstantina
Zafeiropoulou**
Lab Group Member
**Amsterdam University
Medical Center**



David Paez-Espino
Co-Founder & Chief
Technology Officer
Ancilia Biosciences



Dan Brownell
Senior Director, R&D
**AOBiome
Therapeutics**




Rikke Nielsen
Founder & Chief
Executive Officer
BEO Therapeutics



Yongkyu Kim
Chief Executive Officer
Biomatz



Jos Seegers
Senior Director,
Operations
Caelus Health



Jared Kehe
Co-Founder & Chief
Scientific Officer
Concerto Biosciences



Sou Miyake
Head, Venture
Investments
CSB



Isaac Middelmann
EIT Health Accelerator
Director, Strategic
Fundraising
EIT Health



Benjamin Hadida
Co-Founder & Chief
Executive Officer
Exeliom Bio



Aran Singanayagam
Research Group
Leader
**Imperial College
London**



**Gabriela Juárez
Martínez**
Senior Knowledge
Transfer Manager,
Microbiome & AMR
Lead
Innovate UK



Claudio Hidalgo
Chief Executive Officer
**Microviable
Therapeutics**



Jason Goldsmith
Senior Director,
Medical, Translational &
Data Sciences
Nestlé Health Science



Tomas de Wouters
Chief Executive Officer
PharmaBiome



Ping Hu
R&D Director &
Principal Scientist
Procter & Gamble



Livija Deban
Chief Scientific Officer
Prokarium



Denise Kelly
Investment Advisor,
Health For Life
Seventure Partners



Tariq Iqbal
Professor, Clinical
Microbiome
**University of
Birmingham**



Jelena Cvejic
Visiting Professor
KU Leuven



Vittoria Pavoncello
Investment Associate
**Zcube, Zambon
Research Venture**

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Pre-Conference Workshop Day

Tuesday 27th January

Registration & Networking

8:30

Workshop A

9:00-12:00

Uncovering the Role of Artificial Intelligence, Machine Learning & Big Data in Driving Process Development of Microbiome Products

This interactive session explores how to standardise microbiome data from sample collection through to analysis to ensure reproducibility and regulatory confidence.

This workshop will gather experts to:

- Examine best practices for harmonising data pipelines across discovery, development, and clinical stages
- Discuss implementation of FAIR principles to improve data accessibility and interoperability
- Explore how AI and machine learning can accelerate insights, optimise trial design, and support regulatory submissions

Workshop Leaders



Wouter De Jonge
Professor,
Experimental
Gastroenterology
**Amsterdam
University
Medical Center**



Konstantina Zafeiropoulou
Lab Group
Member
**Amsterdam
University
Medical Center**

Lunch Break & Networking

12:00-1:00

Workshop B

1:00-4:00

Breaking Down Silos Between Biotech, Pharma & Consumer Health Companies to Drive Progress From Bench Side to Patients

This strategic workshop brings together stakeholders from biotech, pharma, and consumer health to explore collaboration models, data sharing frameworks, and regulatory pathways.

This workshop will gather experts to:

- Identify shared challenges and opportunities for cross-sector innovation in microbiome therapeutics
- Map out partnership models that align commercial goals with scientific advancement
- Discuss regulatory harmonisation and joint approaches to market access across different product categories

Workshop Leaders



Jason Goldsmith
Senior Director,
Medical,
Translational &
Data Sciences
**Nestlé Health
Science**



Gabriela Juárez Martínez
Senior Knowledge
Transfer Manager,
Microbiome & AMR
Lead
Innovate UK

End of Pre-Conference Workshop Day

4:00

Conference Day One

Wednesday 28th January

10th Annual Microbiome Movement Summit EUROPE
27th-29th January, 2026 | London, UK

WELCOME

7.30 Registration & Networking



8:25 Chair's Opening Remarks

Microbiome Progress Beyond Gastrointestinal Indications: Showcasing Data & Case Studies that Demonstrate Cross-Indication Impact

8.30 Advancing EXL01 Through Clinical Trials & Mechanistic Discovery to Enable Immune Modulation Across Diseases

- Sharing updates from EXL01's active Phase II trials in gastric cancer, NSCLC, hepatocellular carcinoma, Crohn's disease, and C. difficile infection
- Present early clinical signals from investigator-led studies, including preliminary data in infection and IBD
- Highlight EXL01's NOD2-targeted mechanism enabling immune modulation without gut colonisation



Benjamin Hadida
Co-Founder & Chief Executive Officer
Exelium Bio

9:00 Expanding Respiratory Microbiome Insights to Inform Next-Generation Therapeutics

- Showcasing species-level insights from COSMOS metagenomics that identify key airway bacteria regulating immune responses
- Presenting experimental data on microbial metabolites, including short-chain fatty acids, and their role in respiratory immunity
- Highlighting the influence of commensal fungi and highlight early examples of phage therapy in respiratory disease



Aran Singanayagam
Research Group Leader
Imperial College London

9:30 Expanding Indications into Dermatology & Metabolic Disorders to Address Unmet Needs

- Presenting preclinical data on a dual-strain LBP for atopic dermatitis that restores skin barrier function and reduces S. aureus colonisation
- Optimising topical formulation strategies and translational plans for dermatology applications in both human and veterinary models
- Introducing a microbiome-based co-therapy to mitigate GLP-1 side effects in obesity treatment while preserving gut barrier integrity



Yongkyu Kim
Chief Executive Officer
Biomatz

10:00 Morning Refreshments & Speed Networking



Strengthening Mechanistic Understanding & Biomarker Deployment to Accelerate Clinical Validation & Precision Targeting

11:00 Understanding the Gut-Brain Axis & its Role in Modulating Chronic Stress & Non-Communicable Diseases Treatment

- Unpack microbiome-neuroendocrine pathways that influence inflammation and therapeutic efficacy
- Assess the effects of gut-brain signalling on behavioural processes to better understand potential
- Link microbiome modulation to disease outcomes and design clinical trials for non-communicable disease taking this into account



Jelena Helene Cvejic
Visiting Professor
KU Leuven

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Conference Day One

Wednesday 28th January

10th Annual Microbiome Movement Summit EUROPE
27th-29th January, 2026 | London, UK

WELCOME

11:30 Unpacking Mechanistic Insights to Strengthen Microbiome Therapeutic Development

- Explore how AOBiome Therapeutics' recent metabolomic and preclinical work is shaping a deeper understanding of therapeutic action in dermatological indications
- Share lessons learned from bridging mechanistic hypotheses with clinical trial design to improve signal detection and separate from placebo
- Discuss how mechanistic clarity can inform formulation and delivery strategies, and open doors to new indications



Dan Brownell
Senior Director, R&D
AOBiome Therapeutics

12:00 Lunch Break & Networking



Scaling Manufacturing While Reducing Risk & Smoothing the Path to Commercialisation

1:30 Rebuilding Microbiome Drug Development to Tackle Translational & Manufacturing Bottlenecks

- Challenge assumptions around clinical endpoints and trial design to improve translational success
- Address cost-of-goods and production scalability to unlock sustainable development pathways
- Reframe the probiotic-drug divide to clarify modality, mechanism, and market potential



Tomas de Wouters
Co-Founder & Chief
Executive Officer
PharmaBiome

2:00 Positioning the Microbiome Within the Brain Economy to Unlock Cross-Sector Investment & Adoption

- Highlight macroeconomic pressures driving renewed interest in neurodegenerative and behavioural health innovation
- Explore how microbiome innovators can tailor value propositions to attract pharma, public sector and philanthropic partners
- Identify collaboration models that bridge lifestyle, food, and therapeutic approaches for real-world impact



Isaac Middelmann
EIT Health Accelerator
Director, Strategic
Fundraising
EIT Health

2:30 Afternoon Break & Refreshments



Navigating the Funding Landscape, Rebuilding Investor Confidence, & Preparing for Pricing & Reimbursement Success

3:30 Panel Discussion: Rebuilding Investor Confidence in Microbiome Therapeutics to Unlock Capital

- Highlight data-driven milestones that attract funding to unlock capital
- Structure deals to balance risk and reward for early-stage ventures to improve term-sheet appeal
- Position platforms for scalability and exit potential to attract strategic investment



Denise Kelly
Investment Advisor
Seventure Partners



Sou Miyake
Head, Venture Investments
CSB

4:00 Emerging Innovators Showcase: Live Pitches & Strategic Feedback

This dynamic session offers a platform for early-stage microbiome companies to pitch their technologies to a panel of investors, pharma scouts, and industry experts. Designed to foster visibility, feedback, and potential partnerships, each presentation is followed by live commentary and audience engagement.



Vittoria Pavoncello
Investment Associate
Zcube, Zambon Research Venture

5:00 Chair's Closing Remarks & End of Conference Day One

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Conference Day Two

Thursday 29th January

 10th Annual Microbiome Movement Summit EUROPE
27th-29th January, 2026 | London, UK

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

8:20 Registration & Networking



8:55 Chair's Opening Remarks

Latest Clinical & R&D Advances in Gastrointestinal Indications Disorders Driving Therapeutic Innovation

9:00 Ultra-Purified Microbial Fractions: A New Frontier in FMT-Derived Therapeutics

- Showcase a proprietary manufacturing process that isolates microbial fractions while discarding fecal material
- Present preclinical data in infectious disease, melanoma, and colorectal cancer models
- Prepare for IND submission and clinical trial initiation to validate cross-indication potential



Claudio Hidalgo
Chief Executive Officer
Microviable Therapeutics

9:30 Re-evaluating FMT as a Bridge Between Academic Insight & Therapeutic Innovation in IBD

- Introducing trials exploring FMT in ulcerative colitis and PSC to investigate disease modification and mechanistic insight
- Address disconnects between academic research and industry sentiment around FMT and LBPs, and propose frameworks to realign innovation
- Position FMT as both a therapeutic and diagnostic tool to inform future live biotherapeutic development



Tariq Iqbal
Professor, Clinical Microbiome
University of Birmingham

10:00 Morning Break & Poster Session



Enhancing Translational Accuracy Through Advanced Preclinical Models

11:00 Update on BEO 001 Clinical Proof-of-Concept Study

- Ongoing clinical trial in 99 patients to evaluate BEO 001 efficacy and safety
- Predictive response model predicting clinical efficacy



Rikke Nielsen
Chief Executive Officer & Founder
BEO Therapeutics

11:30 Reprogramming the Microbiome: Engineering Phage-Resistant LBPs for Durable Therapeutic Impact

- Demonstrate how CRISPR-enhanced bacterial strains resist phage attack to improve engraftment and therapeutic persistence
- Leverage virome analysis to uncover viral drivers of LBP failure across women's health and gut indications
- Expand platform applications from vaginal microbiome to gut disorders, showcasing data from preclinical developments



David Paez-Espino
Co-Founder & Chief Technology Officer
Ancilia Biosciences

12:00 Lunch Break & Networking



Exploring Novel Modalities & Combination Strategies to Expand Therapeutic Potential

1:30 Exploring Microbiome-Drug Synergies to Strengthen Mechanistic Evidence & Therapeutic Impact

- Present pilot data on combining *Anaerobutyricum soehngenii* with metformin to enhance glycemic control and reduce blood pressure in type 2 diabetes
- Evaluate how microbial therapies can mitigate drug-induced microbiota disruption and amplify host metabolic responses
- Discuss future directions for combination strategies, including prebiotics and multi-strain consortia, and how spatial insights could support mechanistic understanding



Jos Seegers
Senior Director, Operations
Caelus Health

7

+44 (0)20 3141 8700

@ info@hansonwade.com

www.microbiome-europe.com

Microbiome Movement



Conference Day Two

Thursday 29th January

 10th Annual Microbiome Movement Summit
27th-29th January, 2026 | London, UK

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

2:00

Mapping the Microbial World Through Massive Phenotypic Screens & Artificial Intelligence

- Enabled by our MIT-developed combinatorial screening platform kChip, Concerto Biosciences' ecological map of the microbial world incorporates 40+ million experimental measurements of microbial community behavior. This data trains our proprietary AI, kAI, to expand the map further still
- From this unique vantage, hundreds of robust, synergistic, and multifunctional microbe-based ingredient hits stand out in plain view. The first was ENS-002, a three-strain biotherapeutic that successfully completed Phase 1 clinical testing for atopic dermatitis
- We are now unleashing the full might of our platform and data in consumer health, beginning with deodorant and moving toward other applications in skin health and beyond



Jared Kehe
Co-Founder & Chief Scientific Officer
Concerto Biosciences

2.30

Harnessing Microbial Therapeutics to Prime Immunity & Expand Cancer Treatment Possibilities

- Explore IO Prime as a strategy to enhance immune readiness and improve response to existing therapies
- Demonstrate how trained immunity and microbial reprogramming can unlock new combination approaches in oncology
- Understand the rationale behind an upcoming trial using attenuated oral salmonella



Livija Deban
Chief Scientific Officer
Prokarium

3:00

Afternoon Break & Refreshments



Understanding the Global Regulatory Landscape & Accessibility Challenges for Microbiome Therapeutics & Consumer Health Products

3:30

Harnessing Microbial Insights for Innovative Consumer Product Development

- Explore the complex interactions within the human microbiome and how these dynamics influence health and product efficacy in multiple areas including skin and oral care
- Discuss the integration of multiomics technologies, such as RNASeq and metagenomics, proteomics to uncover the mechanisms of microbial response to therapeutic ingredients
- Illustrate case studies from Procter & Gamble that demonstrate how microbiome research translates into actionable strategies for consumer product development, emphasising the role of biomarkers and mechanistic understanding in driving innovation



Ping Hu
R&D Director & Principal Scientist
Procter & Gamble

4:30

Chair's Closing Remarks

5:00

End of Conference

■ This meeting posed a great speaker line-up and plenty of time to connect with colleagues ■

Jacques Ravel, Associate Director, Genomics, & Professor, **Institute for Genome Science, University of Maryland**, Past Attendee

Elevate Your Brand with a Strategic Partnership

As the microbiome's role in human health continues to emerge as one of the most promising areas in science, the discovery, development and commercialisation of microbiome-based therapeutics will accelerate. With progress spanning from early research to clinical application, collaboration across the European microbiome ecosystem is more important than ever.

This is where your expertise becomes essential.

The **10th Microbiome Movement Summit Europe** offers a powerful platform for service providers to engage with innovators shaping the future of microbiome therapeutics. Showcase your capabilities to support advancements in sequencing, bioinformatics, clinical research, and manufacturing, to position your company as the leader in the microbiome space.



Advance Microbiome Sequencing & Bioinformatics

Provide technologies and tools that enable comprehensive sequencing and data analysis of microbiome profiles. Support the identification of novel therapeutic targets and predictive biomarkers for microbiome-related diseases.



End-to-End Manufacturing Solutions for Microbiome Therapeutics

Offer specialised contract manufacturing and development services to scale microbiome-based drug products. Ensure consistency, quality and regulatory compliance to move therapies from bench to market.



Optimise Clinical Trials for Microbiome-Based Therapies

Deliver clinical trial management services tailored to the unique challenges of microbiome drug development. Support patient stratification, trial design and data analysis to generate robust clinical evidence.



Preclinical Research Models for Microbiome Drug Discovery


Provide *in vivo* and *in vitro* research services, including specialised microbiome models. Help drug developers evaluate therapeutic potential and safety before entering clinical trials.



Support Microbiome Research with High-Quality Reagents & Biobanks

Supply essential reagents, culture systems and biobank services to support microbiome research. Facilitate the collection, preservation and analysis of samples for use in drug development and clinical studies.

Seniority of Attendees



C-Suite 31%


VP/Head 16%

Director 28%

Manager 17%

Scientist 7%

Type of Companies Attending



*Statistics Taken from 9th Microbiome Movement Summit Europe

Get Involved



Samuel Turner

Partnerships Director

Tel: +44 (0) 203 141 8700

Email: sponsor@hansonwade.com

Registration Information

Top Reasons to Attend

- 1 Uncover** how pioneering companies are leveraging **data-driven insights** to revolutionise the development of microbiome-based therapeutics.
- 2 Gain** a deeper understanding of the **challenges and opportunities** in microbiome drug development, from discovery through to clinical application.
- 3 Connect** with **top-tier professionals** from biotech, and research organisations to foster collaborations, share knowledge, and drive innovation across microbiome therapies.

3 Easy Ways To Book

-  www.microbiome-europe.com/take-part/register  info@hansonwade.com  +44 (0)20 3141 8700

Drug Developers & Consumer Health Pricing*	Register & Pay by Friday 10th October	On the Door
Full Access Pass: Conference + Workshop Day	£2,097 (Save £900)	£2,997
Conference Only	£1,699 (Save £500)	£2,199
Academic Pricing**	Register & Pay by Friday 10th October	On the Door
Full Access Pass: Conference + Workshop Day	£1,697 (Save £700)	£2,397
Conference Only	£1,299 (Save £500)	£1,799
Service & Solution Providers Pricing	Register & Pay by Friday 10th October	On the Door
Full Access Pass: Conference + Workshop Day	£2,897 (Save £900)	£3,797
Conference Only	£2,299 (Save £500)	£2,799

If you are a UK or EU-based company, you may be subject to a 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number, and the charge will be automatically deducted at checkout.

*To qualify for the drug developer and consumer health rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and start-up rate you must be a full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organisation? Email us at info@hansonwade.com to inquire about attending

Group Discounts

- 10% - 3 Colleagues
- 15% - 4 Colleagues
- 20% - 5+ Colleagues

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time. Group discounts cannot be used in conjunction with other discount codes or offers, other than the early booking rates. For more information on group discount eligibility, rates and booking, please contact: register@hansonwade.com



VENUE

Park Plaza Victoria

239 Vauxhall Bridge Road, SW1V 1EQ, London, UK

For further information or assistance, please visit:
www.radissonhotels.com/en-us/hotels/park-plaza-victoria-london

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organisation can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom